Nadiia Rineiska

Dr. Nadiia Rineiska

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2020 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
SKS. M. Komissarova
S. M. Komissarova
NRNadiia Rineiska
Nadiia Rineiska
NCN. N. Chakova
N. N. Chakova
SNS. S. Niyazova
S. S. Niyazova
Aim To study the clinical course of the mixed phenotype (hypertrophic cardiomyopathy, HCMP, and left ventricular noncompaction, LVNC); to determine its genetic causes; and to evaluate incidence of cardiovascular complications (CVC) during the follow-up period. Material and methods In screening of 286 patients with HCMP, 8 of them (2.8 %; median age, 41.5 years; 4 men and 4 women) from unrelated families were found to have the mixed phenotype (combination of HCMP and LVNC). For their 10 first-degree relatives, the most frequent phenotype was HCMP without LVNC; however, both isolated LVNC and the mixed phenotype were also observed. Criteria for HCMP and LVNC were confirmed by echocardiography and cardiac magnetic resonance imaging Genotyping was performed by high-throughput sequencing NGT using the TruSight Cardio Sequencing Panel kit. Results Probands with the HCMP+LVNC combination compared to first-degree relatives with isolated HCMP and LVNC were characterized by more pronounced left ventricular dysfunction (ejection fraction, 43.57±7.6 and 53.64±6.51 %, respectively; p<0.001), a higher risk of CVC, and a higher incidence of ventricular tachyarrhythmias (7.9 and 2.2 %, respectively; p<0.01). 11 mutations in 5 genes were found in 8 patients with the mixed phenotype. 72.7 % of mutations were in the MYH7 and MYBPC3 genes that encode the heavy chain of β-myosin and myosin-binding protein C, respectively; however, in some cases, replacements in other genes (DTNA, TGFB2) were also found. Conclusion The mixed phenotype (HCMP and LVNC) is associated with more severe clinical course of the disease and unfavorable CVC.

25 November 2025 in Cardiac Research
Verified
Journal Article
Open access
SKSvetlana M. Komissarova
Svetlana M. Komissarova
NRNadiia Rineiska
Nadiia Rineiska
NCNatallia N. Chakova
Natallia N. Chakova
SNSvetlana S. Niyazova
Svetlana S. Niyazova
IHIryna K. Haidzel
Iryna K. Haidzel
Mutations in the DES gene, which encodes the desmin protein, are associated with various forms of skeletal and/or cardiac myopathies. Arrhythmogenic cardiomyopathy (ACM) due to a DES gene mutation is a rare form of desminopathy. In this article, we describe a familial case of biventricular ACM with early subclinical signs of myogenic involvement in the upper and lower limbs, initially manifesting with ventricular arrhythmias and progressive systolic dysfunction. Genetic analysis revealed a likely pathogenic variant c.358G>C (p.Ala120Pro, rs794728996) in exon 1 of the DES gene, located in the N-terminal region of the 1A helix domain. This variant affects filament assembly, leading to cytoplasmic aggregation of desmin, further supporting the functional importance of this region. Early implantation of an implantable cardioverter-defibrillator may contribute to primary prevention of sudden cardiac death in patients carrying this desmin variant. This is the first report of the phenotypic manifestations of the p.Ala120Pro variant in the DES gene in 2 patients with biventricular ACM from the same family.

6 November 2024 in Cardiac Arrhythmias
Verified
Journal Article
Open access
PDF file
SKSvetlana M. Komissarova
Svetlana M. Komissarova
NCNatalya N. Chakova
Natalya N. Chakova
NRNadiia Rineiska
Nadiia Rineiska
SNSvetlana S. Niyazova
Svetlana S. Niyazova
TDTatyana V. Dolmatovich
Tatyana V. Dolmatovich
РМРинейская Надежда Михайловна
Ринейская Надежда Михайловна
AIM: The study was to evaluate the clinical and genetic characteristics of inherited arrhythmias in patients who survived unexplained cardiac arrest. MATERIALS AND METHODS: 20 patients (10 male and 10 female) aged 15 to 55 years (median age 36 [28; 44] years) with documented VT/VF on ECG were observed for 3 years. The clinical and instrumental study included registration of 12-lead ECG, 24-hour Holter ECG, genealogical history collection and family history of sudden cardiac death with ECG assessment of all family members, transthoracic echocardiography, 2D Speckle Tracking echocardiography and cardiac magnetic resonance imaging to exclude structural myocardial changes. High-throughput sequencing (NGS) was utilized to search for mutations in genes linked to the onset of channelopathies and other inherited rhythm disorders. RESULTS: In 4 (20 %) of the 20 probands included in the study, likely pathogenic variants were identified (pathogenicity class IV), and in 7 (35 %) patients, variants with unknown clinical significance (pathogenicity class III) in 10 genes associated with channelopathies (KCNQ1, KCNH2, SCN5A, AKAP9, ANK2, SCN10А, RYR2) and cardiomyopathies (MYH7, JPH2, RBM20). Several genetic variants were found in 3 cases. No significant genetic changes were detected in 9 (45 %) probands. The clinical diagnosis was established during the follow-up period and was verified due to the genetic testing in 5 (25 %) patients. From their ECGs, a prolonged QTc 460 ms was found in 1 patient, Brugada pattern in 2 individuals, and a shortening of QTc up to 323 ms in 1 proband. Subclinical structural changes associated with cardiomyopathies were revealed in 2 patients. In 15 (75 %) patients, it was unfeasible to establish a distinct clinical phenotype. In 6 (30 %) probands, the diagnosis was clarified due to detected genetic variants. CONCLUSION: Clinical manifestations and diverse genetic variants have been studied in patients who have survived unexplained cardiac arrest. In the course of genotyping patients who suffered unexplained cardiac arrest, genetic changes associated with LQTS were detected in 30 % of cases, while the QTc in most cases did not exceed 440 ms, which makes it difficult to establish a diagnosis at an early stage before the development of life-threatening arrhythmic events. The data from our study confirm the idea that in patients with idiopathic ventricular fibrillation, who have suffered unexplained cardiac arrest, cardiac channelopathy or subclinical manifestations of cardiomyopathy are commonly the cause. This phenomenon imposes a need for genetic testing in this category of patients.

27 November 2023 in Cardiac Arrhythmias
Verified
Journal Article
Open access
PDF file
SKSvetlana M. Komissarova
Svetlana M. Komissarova
NRNadiia Rineiska
Nadiia Rineiska
NCNatalya N. Chakova
Natalya N. Chakova
SNSvetlana S. Niyazova
Svetlana S. Niyazova
LPLarisa I. Plashchinskaya
Larisa I. Plashchinskaya
РМРинейская Надежда Михайловна
Ринейская Надежда Михайловна
AIM: of the study was to evaluate the clinical and genetic characteristics, including the development of adverse events and outcomes in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT). MATERIALS AND METHODS: The clinical phenotype of eight patients with CPVT, two of whom were relatives of probands, was observed over 4 years. The clinical and instrumental study included ECG-12, 24-hour Holter ECG monitoring, genealogical history collection and family history of sudden cardiac death (SCD), transthoracic echocardiography and cardiac magnetic resonance imaging to detect structural myocardial changes, electrophysiologic study according to indications, and ICD monitoring. High-throughput sequencing (NGS) was utilized to search for mutations in genes linked to the onset of channelopathies and other inherited rhythm disorders. RESULTS: In 8 patients, nucleotide variants of pathogenicity classes III-V were identified according to the ACMG (2015) criteria in the RYR2 gene associated with CPVT. Pathogenic (IV-V class) and likely pathogenic (IV class) mutations in the RYR2 gene were found in 6 (75%) probands, variants with uncertain clinical significance (VUS, class III) were found in 2 patients. At the time of diagnosis, transient QTc interval prolongation of more than 480 ms was detected in 4 (50%) patients; bradycardia less than 54 beats/min — in 2 (25%) patients, sequences of supraventricular tachycardia and ventricular tachyarrhythmia — in 2 (25%) patients. The most severe form of the disease with marked clinical manifestations and an episode of clinical death with subsequent resuscitation, as well as a transient QTc interval prolongation exceeding 500 ms was observed in patients with mutations c.11814C A (p.Ser3938Arg, rs794728704); c.463G A (p.Gly155Arg) and c.14876G A (p.Arg4959Gln, rs794728811) in the RYR2 gene. Three (37.5%) patients underwent ICD implantation; one for primary SCD prevention and two for secondary prevention. CONCLUSION: In this study, the spectrum of clinical manifestations in patients with genetically confirmed CPVT was examined. The findings highlight transient QTc interval extensions, significant sinus bradycardia, and sequences of supraventricular tachyarrhythmias, which can escalate into life-threatening ventricular tachyarrhythmias in CPVT patients.

10 July 2020 in The Siberian Journal of Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
SKS. S. Komissarova
S. S. Komissarova
EZE. J. Zakharova
E. J. Zakharova
NRNadiia Rineiska
Nadiia Rineiska
IHI. K. Haidel
I. K. Haidel
Determining the clinical course of disease in patients with hypertrophic cardiomyopathy (HCM) with the presence of symptoms of chronic heart failure (CHF) progression remains a complex and unresolved problem.Objective. The objective of the study was to analyze the variants of clinical course in patients with CHF due to progressive LV dysfunction and to evaluate the prognostic role of myocardial fibrosis volume according to late gadolinium enhancement cardiac magnetic resonance (CMR) as a predictor of CHF progression to NYHA FC III.Material and Methods. A comprehensive examination including cardiac echocardiography, Holter ECG monitoring, and late gadolinium enhancement CMR, was performed in 124 patients (79 men and 45 women, median age of 46 years) with HCM who were observed in Republican Scientific and Practical Centre “Cardiology”. The median follow-up was 41 months (from 25 to 58 months). The clinical endpoint was progression of CHF symptoms from NYHA FC I–II to class III requiring hospitalization.Results and Discussion. Among 124 patients with HCM, CHF progression requiring hospitalization during the follow-up period was observed in 24 patients with preserved systolic function (LV EF > 50%). The 5-year survival rate was 83% (95% CI 76.5–90.1). As a new marker aimed at identifying patients at risk of CHF progression, the volume of myocardial fibrosis was analyzed using the late gadolinium enhancement cardiac MR. The level of fibrosis, associated with the progression of heart failure, was 20%. The log-rank test and Kaplan-Meier survival curves showed statistically significant diff erences (p = 0.001) in groups with fibrosis volume less than 20% and more than 20%. Event-free survival was 95.2% (95% CI 89.9–100%) and 32.1% (95% CI 17.9–57.4%), respectively. Multivariate analysis showed that the independent factors associated with CHF progression and associated hospitalization were age over 50 years (HR 5.9; 95% CI 2.3–15.1, p < 0.001), atrial fibrillation (AF) episodes (HR 5.6; 95% CI 2.2–14.2, p < 0.001), and percentage of myocardial fibrosis volume ≥20% according to cardiac MR data (HR 23.3; 95% CI 7.3–74.8, p < 0.001).Conclusion. Based on the results of a multi-factor analysis, we identified a group of HCM patients at risk of CHF progression requiring hospitalization. These patients were over 50 years of age, had AF episodes, and a myocardial fibrosis volume ≥20%.

22 April 2024 in Russian Cardiology Bulletin
Verified
Journal Article
Closed access
SKS.M. Komissarova
S.M. Komissarova
NRNadiia Rineiska
Nadiia Rineiska
OMO.P. Melnikova
O.P. Melnikova
AEA.A. Efimova
A.A. Efimova
Objective. To estimate prognostic value of RV dysfunction for adverse events and outcomes in patients with left ventricular non-compaction cardiomyopathy. Material and methods. There were 218 patients with left ventricular non-compaction cardiomyopathy (141 men and 77 women, median age 38.8 [30.0; 50.4] years). In addition to conventional examination, all patients underwent cardiac contrast-enhanced magnetic resonance imaging. The primary composite endpoint were the following adverse events and outcomes: hospitalization due to progression of CHF, implantation of ICD/ CRT-D for sustained VT/VF, orthotopic heart transplantation, all-cause mortality. The secondary composite endpoint were life-threatening ventricular arrhythmias requiring ICD/CRT-D implantation and all-cause mortality. Results. RV dysfunction was detected in 66 (31.1%) out of 212 patients. RV EF correlated with LV dysfunction (r=0.597, p<0.001). According to cardiac contrast-enhanced magnetic resonance imaging, myocardial fibrosis was more common in patients with RV dysfunction compared to patients with preserved RV function (38 (57.6%) and 57 (39%), respectively, p=0.012). During the follow-up period (median 60 months [10; 106]), 96 (45.3%) patients reached the composite primary point. RV dysfunction was significantly associated with shorter period until composite primary (HR 3.43; 95% CI 2.24—5.26) and secondary endpoints (HR 3.11; 95% CI 2.02—4.79). Independent predictors of primary composite endpoint were LVEF <45% and myocardial fibrosis. Conclusion. RV dysfunction was more common in patients with severe symptoms of HF and myocardial remodeling, including LV dysfunction and myocardial fibrosis. RV dysfunction was associated with shorter period until composite endpoints (hospitalization due to progression of CHF, orthotopic heart transplantation, arrhythmic events with implantation of ICD/CRT-D and all-cause mortality).